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Objective: To evaluate long-term efﬁcacy and safety proﬁles during 3 years of individualized ranibizumab
treatment in patients with visual impairment due to diabetic macular edema (DME).
Design: Phase IIIb, multicenter, 12-month, randomized core study and 24-month open-label extension study.
Participants: Of the 303 patients who completed the randomized RESTORE 12-month core study, 240
entered the extension study.
Methods: In the extension study, patients were eligible to receive individualized ranibizumab treatment as of
month 12 guided by best-corrected visual acuity (BCVA) and disease progression criteria at the investigators’
discretion. Concomitant laser treatment was allowed according to the Early Treatment Diabetic Retinopathy
Study guidelines. Based on the treatments received in the core study, the extension study groups were referred to
as prior ranibizumab, prior ranibizumab þ laser, and laser.
Main Outcome Measures: Change in BCVA and incidence of ocular and nonocular adverse events (AEs)
over 3 years.
Results: Overall, 208 patients (86.7%) completed the extension study. In patients treated with ranibizumab
during the core study, consecutive individualized ranibizumab treatment during the extension study led to an
overall maintenance of BCVA and central retinal subﬁeld thickness (CRST) observed at month 12 over the 2-year
extension study (þ8.0 letters, 142.1 mm [prior ranibizumab] and þ6.7 letters, 145.9 mm [prior ranibizumab þ
laser] from baseline at month 36) with a median of 6.0 injections (mean, 6.8 injections; prior ranibizumab) and 4.0
(mean, 6.0 injections; prior ranibizumab þ laser). In the prior laser group, a progressive BCVA improvement (þ6.0
letters) and CRST reduction (142.7 mm) at month 36 were observed after allowing ranibizumab during the
extension study, with a median of 4.0 injections (mean, 6.5 injections) from months 12 to 35. Patients in all 3
treatment groups received a mean of <3 injections in the ﬁnal year. No cases of endophthalmitis, retinal tear, or
retinal detachment were reported. The most frequently reported ocular and nonocular adverse effects over 3
years were cataract (16.3%) and nasopharyngitis (23.3%). Eight deaths were reported during the extension study,
but none were suspected to be related to the study drug/procedure.
Conclusions: Ranibizumab was effective in improving and maintaining BCVA and CRST outcomes with a
progressively declining number of injections over 3 years of individualized dosing. Ranibizumab was generally
well tolerated with no new safety concerns over 3 years. Ophthalmology 2014;121:1045-1053
ª 2014 by the American Academy of Ophthalmology.
*Supplemental material is available at www.aaojournal.org.
Open access under CC BY-NC-ND license.Diabetic macular edema (DME) is one of the leading causes of
visual impairment in the working-age population in developed
countries.1 In addition to DME, patients with diabetes also are
prone to multiple systemic comorbidities.2 For this large
population with chronic disease requiring extended lifelong
therapy in a challenging environment, it is particularly
important to identify manageable DME treatment strategies 2014 by the American Academy of Ophthalmology
Published by Elsevier Inc.Open access under CC BY-NC-ND license.that provide long-term safety and efﬁcacy proﬁles. Although
focal/grid laser photocoagulation is an established treatment
option for patients with visual impairment due to DME and is
known to stabilize vision, it does not appear to be effective in
improving vision in the majority of patients.3 Thus, there is a
need for treatments that are safe and manageable and that can
improve vision in patients with DME. Ranibizumab is a1045http://dx.doi.org/10.1016/j.ophtha.2013.11.041
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designed for ocular use. It binds to vascular endothelial
growth factor (VEGF)-A with high afﬁnity, inhibits multiple
isoforms of VEGF-A, and has minimal systemic exposure
after intravitreal injection.4 Ranibizumab (Lucentis; Novartis,
Basel, Switzerland and Genentech Inc., South San Francisco,
CA) is approved in many countries for 4 major indications:
neovascular age-related macular degeneration, visual impair-
ment due to DME, visual impairment secondary to macular
edema in branch or central retinal vein occlusion, and visual
impairment due to choroidal neovascularization secondary to
pathologic myopia.5
Several studies with different dosing regimens and treatment
algorithms have established the efﬁcacy and safety proﬁles of
ranibizumab treatment in patients with DME. Long-term data
recently became available, allowing the evaluation of continued
therapy effects and recognizing patterns of chronic disease ac-
tivity. The Ranibizumab Injection in Subjects with Clinically
Signiﬁcant Macular Edema with Center Involvement Second-
ary toDiabetesMellitus (RISE [N¼ 377] andRIDE [N¼ 382])
studies demonstrated that monthly ranibizumab treatment over
24 months was well tolerated and associated with superior best-
corrected visual acuity (BCVA) outcomes compared with
monthly sham injections.6 Two-year results of the Diabetic
Retinopathy Clinical Research Network (DRCR.net; N ¼ 691)
and Ranibizumab for Edema of the mAcula in Diabetes
(READ-2; N ¼ 126) studies demonstrated that ranibizumab
alone or in combination with laser (prompt/deferred) provided
superior and sustained BCVA gains compared with laser
photocoagulation monotherapy using an individualized dosing
algorithm.7,8 Of note, the 3-year results of the DRCR.net study
reported complete BCVA maintenance from year 2 to year 3
with only 1 to 2 (median) injections in year 3.9 The DRCR.net
study also permitted less frequent than monthly follow-up for
patients with stable absence of macular edema. The median
number of clinic visits in the third year of the DRCR.net study
was 7 to 8.9 The 3-year outcomes of the READ-2 study sug-
gested that aggressive retreatment as per individual patient
needs based on continued or recurrent activity deﬁned by
intraretinal ﬂuid at the central macula resulted in BCVA
improvement and reduction in central retinal subﬁeld thickness
(CRST).10 In contrast to these studies, in the RESTORE study
ranibizumab treatment was administered using an
individualized dosing regimen based on BCVA stability and
disease progression criteria, in line with the current
ranibizumab label in European Union (EU).5 The RESTORE
study aims to address the need to optimally manage patients
with diabetes by assessing the long-term safety and efﬁcacy
proﬁles and the re-treatment needs for ranibizumab.
The RESTORE core study (registered as NCT00687804 at
http://clinicaltrials.gov/; accessed June 25, 2013) demonstrated
that ranibizumab alone or combined with laser provided su-
perior visual acuity (VA) gains when compared with laser
monotherapy in patients with visual impairment due to DME
over 12 months.11 Similar to the core study, in the RESTORE
extension study, ranibizumab was administered according to
an individualized dosing regimen based on the investigators’
discretion; treatment was guided by BCVA stability and
disease progression criteria, with monthly monitoring. All
patients who completed the core study were eligible to1046receive ranibizumab treatment during the extension study.
The ﬁrst year interim results of this extension study
demonstrated that ranibizumab treatment was well tolerated
and no new ocular or nonocular safety concerns were
observed over 2 years. Furthermore, the individualized
dosing regimen was successful in maintaining (prior
ranibizumab groups) and improving (prior laser group) the
BCVA gains observed at the end of the core study over the
ﬁrst year of the extension study.12
The consecutive analysis presented in this article describes
the extended efﬁcacy and safety ﬁndings of individualized
ranibizumab 0.5 mg treatment based on the complete 3-year
data of the RESTORE core and extension studies conducted
in patients with visual impairment due to DME.
Methods
Study Design
The RESTORE extension study was a phase IIIb, 24-month, open-
label, multicenter study (month 12 to month 36) conducted in pa-
tients with DME who completed the 12-month RESTORE core study
(day 1 to month 12; Fig 1, available at www.aaojournal.org). In the
RESTORE core study, patients were randomized to receive
ranibizumab, ranibizumab þ laser, or laser alone. In the extension
study, all patients could receive individualized ranibizumab
treatment according to the prespeciﬁed stability-based BCVA and
the disease progression re-treatment criteria. During the extension
study, the investigators remained masked to the treatment adminis-
tered during the core study. All patients were eligible to receive laser
pro re nata (PRN) in accordance with Early Treatment Diabetic
Retinopathy Study (ETDRS) guidelines at the investigators’ discre-
tion. The study was conducted in accordance with the Declaration of
Helsinki, and every patient provided new written informed consent
before entering the extension study. The study is registered with
clinicaltrials.gov (accessed June 25, 2013; NCT00906464).
Patients
The RESTORE core study enrolled 345 patients aged18 years with
type 1 or 2 diabetes mellitus (per American Diabetes Association or
WorldHealthOrganization guidelines), hemoglobin (Hb)A1c10%,
and visual impairment due toDMEwith a BCVA letter score between
78 and 39 letters, based on ETDRS-like VA testing charts at a testing
distance of 4 m (approximate Snellen equivalent 20/32e20/160).
Patients who completed the randomized 12-month RESTORE
core study assessments and provided new written informed con-
sents for the extension were included in the RESTORE extension
study. Key exclusion criteria for the extension study were history
of stroke or transient ischemic attack; hypersensitivity to ranibi-
zumab or any component of the ranibizumab formulation; uncon-
trolled glaucoma in either eye (intraocular pressure [IOP] >24
mmHg with medication or according to investigator’s judgment);
evidence of vitreomacular traction (in either eye) or active prolif-
erative diabetic retinopathy (study eye); use of other investigational
drugs at the time of enrollment or within 30 days or 5 half-lives
before enrollment, whichever was longer; and ocular conditions
in the study eye that required chronic concomitant therapy with
topical ocular corticosteroids.
Objectives
The primary objective of the RESTORE extension study was to
evaluate the safety proﬁle of ranibizumab 0.5 mg on the basis of
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the 24-month extension study period (i.e., months 12e36). Sec-
ondary objectives were to describe the ocular and nonocular AEs
over 36 months (i.e., day 1 to month 36) in patients treated with
ranibizumab 0.5 mg and to evaluate the change in BCVA from
core baseline over 24 months of the extension study (i.e., months
12e36) and over 36 months of the entire study period.
Treatment
The RESTORE extension was an open-label study. All patients
enrolled in the extension study were eligible to receive intravitreal
ranibizumab 0.5 mg injections on the basis of the prespeciﬁed
retreatment criteria, andmonthly visitsweremandated for each patient.
Ranibizumab 0.5 mg was administered as an intravitreal in-
jection under aseptic conditions, which includes the use of surgical
hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid
speculum. Patients were treated at monthly intervals until stable
vision was achieved, that is, no further BCVA improvement
attributable to treatment was observed compared with the 2 pre-
vious consecutive visits according to the investigator or a BCVA
letter score of 84 letters (approximate Snellen equivalent of 20/
20) was observed. If, on the basis of the investigators’ opinion, a
decrease in BCVA due to DME was observed, monthly ranibizu-
mab treatment was resumed until stable BCVA was reached.
Ranibizumab injection at the baseline of the extension study (i.e.,
month 12) was not mandated, and a maximum of 24 monthly
ranibizumab injections could be administered during the extension
study (months 12e35). Also, patients previously treated with laser
monotherapy who entered the extension study did not mandatorily
receive the 3 initial injections that were administered to patients in
the ranibizumab groups at the beginning of the core study. During
the 2-year extension study, all patients also were eligible to receive
laser treatment (recorded as concomitant medication during the
extension study) at a minimum interval of 90 days, according to the
ETDRS guidelines at the investigators’ discretion. Decisions on
treatment with laser were independent of decisions to inject rani-
bizumab and vice versa. If in the opinion of the investigator, both
ranibizumab and laser treatment were required on the same day,
laser was always administered before ranibizumab injection.
Efﬁcacy and Safety Assessments
Efﬁcacy Assessments. The BCVA of the study eye (evaluated
through the change vs. baseline of core and extension studies, pro-
portion of patients gaining and losing 10 and 15 BCVA letters,
respectively, and the proportion of patients with BCVA score >78
and <39 ETDRS letters was assessed at every visit as described
previously.11 The VA measurements were taken in a sitting position
using the ETDRS-like VA testing charts at a testing distance starting
at 4 m. The VA was assessed by certiﬁed personnel to ensure
standardized BCVA assessments at each visit before applying any
potential new dose of ranibizumab.
Anatomic end points included change in CRST (assessed by
Stratus Optical Coherence Tomography; Carl Zeiss Meditec Inc.,
Dublin, CA), proportion of patients with a 3-step change from
baseline in the ETDRS severity score, and retinal ischemia (re-
ported as change from baseline in foveal avascular zone, evaluated
through the central subﬁeld capillary loss variable) and were
assessed as described previously.11 These end points were assessed
by the Central Reading Center.
The patients’ subjective assessment of visual functioning was
assessed using the National Eye Institute Visual Functioning
questionnaire-25 (NEI VFQ-25). The assessed end points included
change in NEI VFQ-25 scores (composite, general vision, near
activities, and distance activities).Treatment Exposure. The number and frequency of ranibizu-
mab injections and active laser treatments (recorded as concomitant
medication during the extension study) were evaluated during the
extension study. Reasons for ranibizumab treatment interruption in
the extension study were documented.
Safety Assessments. Safety assessments included monitoring
and recording all ocular and nonocular AEs and serious AEs
(SAEs). Safety was assessed by standard ophthalmic examinations,
IOP measurements, vital signs, and laboratory parameters, as
described previously.11 Laboratory assessments for safety
parameters were performed by a certiﬁed central laboratory. All
ocular/nonocular AEs and SAEs, including information on their
relationship to study drug/procedure, were recorded at every visit.
Adverse events were summarized by the proportion of patients
experiencing any type of AEs and grouped per the standardized
Medical Dictionary for Regulatory Activities system organ classes
and preferred terms.
The AEs of potential safety concerns (hypersensitivity, hyper-
tension, nonocular hemorrhage, proteinuria, myocardial infarction,
venous thromboembolic events, and other arterial thromboembolic
events), identiﬁed on the basis of prior experience with ranibizu-
mab in clinical trials, were recorded.
Statistical Analysis
All analyses in the extension study were presented by treatment
groups as in the core study, namely, ranibizumab, ranibizumab þ
laser, and laser alone, and are now referred to as prior ranibizumab,
prior ranibizumab þ laser, and prior laser groups, respectively. No
comparison of treatment groups by means of statistical hypothesis
testing was intended. Data were summarized for 2 time periods: (1)
24-month analysis (analysis of data from the extension study, i.e.,
months 12e36) and (2) 36-month analysis (analysis of data from
the core and extension studies, i.e., day 1 to month 36).
All analyses were performed on the safety set, consisting of all
patients who entered and had at least 1 safety assessment in the
extension study. Adverse events were summarized by the number
and proportion of patients experiencing AEs by system organ
classes and preferred terms. Descriptive statistics (including num-
ber of observations, mean, and standard deviation or standard er-
ror) were provided separately for each treatment group. A last
observation carried forward approach was used for imputation of
missing data in the BCVA, CRST, ETDRS severity score, retinal
ischemia, and NEI VFQ-25 analysis. All comparisons between day
1 and month 36 and month 12 and month 36 results in this article
are made only for the 240 patients who participated in both the core
and extension studies.Results
Patient Disposition and Demographics
Of the 303 patients with DME who completed the core study, 240
provided signed informed consent and were enrolled in the
extension study. Although the reasons for nonenrollment into the
extension study were not formally documented, the majority of the
remaining 63 patients could not be enrolled into the extension
study because of administrative reasons, such as late approvals
from the institutional review board/independent ethics committee
or late contract agreements. All analyses were performed on the
safety set, which comprised 83 (prior ranibizumab), 83 (prior
ranibizumab þ laser), and 74 (prior laser) patients. Of the 240
enrolled patients, 208 (86.7%) completed the extension study (Fig
2, available at www.aaojournal.org). The proportion of patients
who completed the study and the month 36 visit was similar1047
Figure 3. Mean of the change in best-corrected visual acuity (BCVA) letter score from baseline (day 1) to month 36 (A) and mean of the change in central
retinal subﬁeld thickness (CRST) score from baseline to month 36 (B) (safety set [last observation carried forward]). ETDRS ¼ early treatment diabetic
retinopathy study; PRN ¼ pro re nata; SE ¼ standard error.
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prior ranibizumab þ laser: 86.7%, and prior laser: 85.1%).
Withdrawal of consent (4.6%), death (3.3%), and AEs (2.5%)
were the most common reasons for patient discontinuation of the
extension study across all the prior treatment groups (Fig 2,
available at www.aaojournal.org).
The core baseline demographics and disease characteristics (at day
1) for patients entering the extension study were similar across all the
prior treatment groups (Table 1, available at www.aaojournal.org). At
the baseline of the extension study (month 12), the disease
characteristics of patients treated with laser and those treated with
ranibizumab in the core study were comparable except for BCVA,
which was slightly lower in patients treated with laser alone in the
core study (Table 2, available at www.aaojournal.org).
Efﬁcacy Proﬁle
Best-Corrected Visual Acuity. The mean of the change in BCVA
from baseline over 3 years is shown in Figure 3A. In patients1048treated with ranibizumab in the core study, the mean BCVA gain
(letters  standard error) at month 12 (7.9  0.81 [prior
ranibizumab]; 7.1  0.80 [prior ranibizumab þ laser]) was in
general maintained from month 12 to 36 (prior ranibizumab: 8.0
 1.11; prior ranibizumab þ laser: 6.7  1.05 at month 36). Of
note, prior laser-treated patients, who were eligible to receive
ranibizumab treatment in the extension study, showed a progres-
sive improvement of BCVA from 2.3  1.11 letters at month 12 to
6.0  1.09 letters at month 36.
At month 36, 42.2% of patients in the prior ranibizumab group,
28.9% of patients in the prior ranibizumabþ laser group, and 17.6%
of patients in the prior laser group had a BCVA score >78 letters,
whereas only 1 patient (1.2%), 1 patient (1.2%), and 2 patients
(2.7%), respectively, had a BCVA of <39 letters at month 36. Over
the 3-year study period, a similar proportion of patients gained 10
and 15 BCVA letters across the 3 groups (Fig 4). However, at
month 36, a greater proportion of patients treated with laser alone
in the core study lost 10 letters (prior ranibizumab: 2.4%; prior
ranibizumab þ laser: 4.8%; prior laser: 8.1%) and 15 letters (prior
Figure 4. Categorized change in best-corrected visual acuity (BCVA) from
baseline (day 1) to month 36 (safety set [last observation carried forward]).
Table 3. Mean Number of Ranibizumab Treatments Received
over 3 Years (Day 1 to Month 35, Safety Set)
Treatment Period
Mean No. of Ranibizumab Injections
Prior Ranibizumab
0.5 mg (n ¼ 83)
Prior
Ranibizumab
0.5 mg þ Laser
(n ¼ 83)
Prior
Laser
(n ¼ 74)
Day 1 to month 35 14.2 13.5 6.5*
Day 1 to month 11 7.4 7.5 0.0
Months 12e23 3.9 3.5 4.1
Months 24e35 2.9 2.5 2.4
*Includes ranibizumab 0.5 mg injections given over months 12e35 only.
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2.7%) when compared with patients primarily treated with
ranibizumab in both the core and extension studies.
Central Retinal Subﬁeld Thickness. In patients treated with
ranibizumab in the core and extension studies, the mean CRST
reductions observed at the end of the core study (prior
ranibizumab: 127.8 mm; prior ranibizumab þ laser: 139.7 mm at
month 12) were maintained at month 36 (prior ranibizumab: 142.1
mm; prior ranibizumabþ laser:145.9 mm). At month 12, a relatively
lower mean reduction in CRST (63.3 mm) was observed in the prior
laser-treated patients compared with patients in the prior ranibizumab
group. A progressive reduction of 79.4 mm was observed in the prior
laser-treated patients with the allowance of ranibizumab treatment from
month 12 to 36 (mean change from baseline to month 36,142.7 mm;
Fig 3B).
Retinal Ischemia. The mean of the changes in the size of the
foveal avascular zone from baseline to month 36 were 0.027 mm2
(median, 0.049 mm2; prior ranibizumab), 0.051 mm2 (median, 0.027
mm2; prior ranibizumab þ laser), and 0.399 mm2 (median, 0.013
mm2; prior laser).
Early Treatment Diabetic Retinopathy Study Severity
Score. At month 36, 14.8% of patients in the prior ranibizumab
group, 28.3% of patients in the prior ranibizumab þ laser group,
and 16.0% of patients in the prior laser group had an improvement
in ETDRS severity score (3 steps) from baseline, whereas 1.6%,
7.5%, and 4.0% of patients, respectively, had a worsening of
ETDRS score (3 steps) from baseline to month 36.
Visual Functioning Questionnaire. Over 3 years, patients
treated with ranibizumab in both the core and extension studies
showed an overall improvement of NEI VFQ-25 scores at month
36 when compared with the core baseline (composite scores: 5.0
[prior ranibizumab], 4.3 [prior ranibizumab þ laser]; general
vision: 6.0 [prior ranibizumab], 7.1 [prior ranibizumab þ laser];
near activities: 12.2 [prior ranibizumab], 7.8 [prior ranibizumab þ
laser]; distance activities: 2.6 [prior ranibizumab], 4.1 [prior
ranibizumab þ laser]). In both the prior ranibizumab and prior
ranibizumab þ laser groups, the initial gains in the NEI VFQ-25
scores observed at month 12 were mostly maintained for the
composite (prior ranibizumab: 6.5 [month 12] and 5.0 [month 36];
prior ranibizumab þ laser: 4.8 [month 12] and 4.3 [month 36]),
general vision (prior ranibizumab: 8.7 [month 12] and 6.0 [month
36]; prior ranibizumab þ laser: 8.0 [month 12] and 7.1 [month
36]), distance activity (prior ranibizumab: 6.4 [month 12] and 2.6
[month 36], and near activity (prior ranibizumab: 10.7 [month 12];
12.2 [month 36]; prior ranibizumab+laser: 9.3 [month 12]; 7.8
[month 36]) prior ranibizumab þ laser: 4.5 [month 12] and 4.1
[month 36]) subscale scores until month 36. After allowance ofranibizumab treatment as of month 12, patients in the prior laser
group showed a progressive improvement in near activities (month
12: 1.9; month 36: 8.4), general vision (month 12: 1.6; month 36:
8.1), distance activities (month 12: 1.8; month 36: 3.5), and
composite scores (month 12: 2.4; month 36: 3.9) from months 12
to 36.
Treatment Exposure
Ranibizumab Injections. Patients who received ranibizumab pre-
viously in the core study and continued with individualized ranibi-
zumab treatment in the extension study (prior ranibizumab and prior
ranibizumab þ laser) received a median of 12.0 (mean: prior rani-
bizumab [14.2]; prior ranibizumabþlaser: [13.5]) ranibizumab in-
jections over 3 years (day 1 to month 35; Table 3 and Table 4,
available at www.aaojournal.org). The mean number of
ranibizumab injections administered over 2 years of the extension
study (months 12e35) was similar across the 3 groups, with a
progressive reduction in re-treatment need from the ﬁrst to the
second year and the third year (median, 6.0; mean, 6.8 [prior
ranibizumab]; median, 4.0; mean, 6.0 [prior ranibizumab þ laser],
and median, 4.0; mean, 6.5 [prior laser]). A similar proportion of
patients across the 3 groups did not receive any injections over
months 12 to 35 (prior ranibizumab: 19.3%; prior ranibizumab þ
laser: 25.3%; and prior laser: 20.3%; Table 4, available at
www.aaojournal.org). Therefore, 59 of the 74 prior laser-treated
patients (79.7%) received an average of 8.1 ranibizumab injections
from months 12 to 35.
In the 24-month extension study (months 12e35), disease
improvement was the most frequent reason for treatment inter-
ruption/stop. In the prior laser-treated patients, ranibizumab in-
jections over months 12 to 35 resulted in disease improvement and
subsequent treatment interruption in 93.2% of patients (Table 5,
available at www.aaojournal.org).
Laser Treatment. The mean number of laser treatments
administered to the study eye during the extension study (months
12e36; recorded as concomitant medication) ranged from 0.1 to
0.4 across the prior treatment groups (median, 0.0 for all treatment
groups). In the extension study, the majority of patients (75.9%e
91.6%) across all groups did not require/receive laser treatment
(Table 6, available at www.aaojournal.org).
Safety Proﬁle
Serious Adverse Events. Overall, ocular SAEs (study eye) were
reported in 8 patients (3.3%; Table 7, available at www.
aaojournal.org) over the 3-year study period (day 1 to month
36); the most frequently observed ocular SAE was cataract (prior
ranibizumab þ laser: 3 [3.6%], prior laser: 2 [2.7%]). The most
frequently occurring ocular SAEs in the extension study (months1049
Table 9. Most Frequent Ocular (Study Eye) and Nonocular Adverse Events in the Extension Study (Months 12e36;
5% in Any Group, Safety Set)
Preferred Terms
Prior
Ranibizumab 0.5 mg (n [83)
Prior
Ranibizumab 0.5 mg D Laser
(n [ 83)
Prior
Laser
(n [ 74)
Ocular AEs (study eye), total 47 (56.6) 47 (56.6) 37 (50.0)
Eye pain 9 (10.8) 6 (7.2) 9 (12.2)
Cataract 7 (8.4) 12 (14.5) 8 (10.8)
Dry eye 3 (3.6) 3 (3.6) 5 (6.8)
Lacrimation increased 2 (2.4) 3 (3.6) 5 (6.8)
Macular ﬁbrosis 1 (1.2) 2 (2.4) 4 (5.4)
Nonocular AEs, total 61 (73.5) 61 (73.5) 53 (71.6)
Nasopharyngitis 12 (14.5) 12 (14.5) 15 (20.3)
Inﬂuenza 7 (8.4) 6 (7.2) 7 (9.5)
Hypertension 7 (8.4) 7 (8.4) 5 (6.8)
Back pain 3 (3.6) 2 (2.4) 5 (6.8)
Dizziness 2 (2.4) 0 (0.0) 4 (5.4)
Renal failure 0 (0.0) 2 (2.4) 4 (5.4)
AE ¼ adverse event.
Data are no. (%). Preferred terms are sorted in descending frequency, as reported in ranibizumab 0.5 mg column; a subject with multiple occurrences of an
AE under 1 treatment is counted only once in the AE category for that treatment.
Ophthalmology Volume 121, Number 5, May 201412e36) are presented in Table 8 (available at www.
aaojournal.org). During the extension study (months 12e36),
cataract was observed as an ocular SAE in 1 patient in the prior
ranibizumab þ laser group. Over the 3-year study period, none
of the ocular SAEs of the study eye were suspected by the
investigator to be related to the study drug or procedure.
Overall, 88 patients (36.7%) experienced nonocular SAEs
(Table 7, available at www.aaojournal.org) over 3 years (prior
ranibizumab: 30 [36.1%], prior ranibizumab þ laser: 31 [37.3%],
and prior laser: 27 [36.5%]). The key nonocular SAEs reported
over this 3-year period included coronary artery disease (prior
ranibizumab: 3 [3.6%]; prior laser: 1 [1.4%]), angina pectoris (prior
ranibizumab: 2 [2.4%]; prior ranibizumabþ laser: 1 [1.2%]), cardiac
failure (each prior ranibizumab group: 1 [1.2%]; prior laser: 4
[5.4%]), cerebrovascular accident (prior ranibizumab: 2 [2.4%];
prior ranibizumab þ laser: 1 [1.2%]; prior laser: 1 [1.4%]), and
myocardial infarction (prior ranibizumab þ laser: 3 [3.6%]; prior
laser: 3 [4.1%]). Nonocular SAEs reported during the extension
study (months 12e36) are presented in Table 8 (available at
www.aaojournal.org), and those suspected by the investigator to
be related to the study drug/procedure over 2 years are indicated.
Of the 240 patients entering the extension, 8 deaths were reported
during the 24-month extension study, that is, over months 12 to 36 (2
in the prior ranibizumab group and 3 each in the prior ranibizumabþ
laser and prior laser groups); none were suspected to be related to the
study drug or procedure. Nonocular SAEs reported during the
extension study (months 12e36) are presented inTable 8 (available at
www.aaojournal.org), and those suspected by the investigator to be
related to the study drug/procedure over 2 years are indicated.
Adverse Events. The most frequently observed ocular AEs in the
study eye during the extension study (months 12e36)were cataract (27
[11.3%]) and eye pain (24 [10.0%]); the most frequently occurring
ocular AEs in the study eye during the extension study (months 12e36;
5% in any group) are summarized in Table 9. The most frequent
ocular AEs (5% in any group; summarized in Table 10, available
at www.aaojournal.org) in the study eye across the treatment groups
over the 3 years were cataract (39 [16.3%]), eye pain (37 [15.4%]),
conjunctival hyperemia (21 [8.8%]), and conjunctival hemorrhage
(18 [7.5%]). Of the 240 patients entering the extension study,
increased IOP in study eye was observed in 9 patients (3.8%) only1050across the prior ranibizumab treatment arms over 3 years. The most
frequent ocular AEs in the study eye suspected by the investigator to
be related to study drug/procedure across all treatment groups over
the 3 years (day 1 to month 36) and during the extension study
(months 12e36) were eye pain and conjunctival hemorrhage (the
latter was observed only in patients who received ranibizumab in the
core or extension studies) (Tables 11 and 12, available at www.
aaojournal.org). No cases of endophthalmitis were reported in any of
the treatment arms over the entire 3-year study period.
Nasopharyngitis (39 [16.3%]), inﬂuenza (20 [8.3%]), and hy-
pertension (19 [7.9%]) were the most common nonocular AEs re-
ported in the extension study (months 12e36). The most frequently
occurring ocular and nonocular AEs in the extension study were
comparable across all groups (Table 9). Nasopharyngitis (56
[23.3%]) and hypertension (32 [13.3%]) were the most common
nonocular AEs reported from day 1 to month 36, followed by
inﬂuenza (28 [11.7%]) and back pain (20 [8.3%]) (Table 10,
available at www.aaojournal.org). Nonocular AEs suspected to be
related to the study drug/procedure over day 1 to month 36 and
months 12 to 36 are summarized in Tables 11 and 12 (available at
www.aaojournal.org), respectively.
Adverse Events Leading to Study Drug Discontinuation.
Over the 3-year study period, 1 patient each in the prior
ranibizumab þ laser and prior laser groups experienced ocular AEs
in the study eye, leading to study drug discontinuation (Table 13,
available at www.aaojournal.org). Nonocular AEs leading to
study drug discontinuation over 3 years are summarized in
Table 13 (available at www.aaojournal.org).
Adverse Events Related to Potential Safety Concerns. Adverse
events related to potential safety concerns over 3 years and in the
extension study are summarized in Tables 14 and 15, respectively
(available at www.aaojournal.org). No cases of endophthalmitis,
retinal tear, or retinal detachment were observed in the extension
study.
Discussion
The 3-year results from the RESTORE core and extension
studies provide robust data on the long-term safety proﬁle
Schmidt-Erfurth et al  Long-term Efﬁcacy and Safety Proﬁles of Ranibizumab in DMEand the re-treatment need of intravitreal ranibizumab in
patients with DME. Patients were treated on the basis of an
individualized as-needed regimen similar to the recom-
mendation in the EU label. Therefore, the ﬁndings of this
study may closely reﬂect outcomes expected in routine
clinical practice with ranibizumab treatment for DME based
on the EU label.
At month 12, the RESTORE extension patients initially
treated with ranibizumab showed a considerable improve-
ment in BCVA compared with those treated with laser alone
in the core phase. During the extension study, patients in the
prior ranibizumab groups were able to maintain the initial
BCVA gains achieved at month 12 to months 24 and 36
with individualized ranibizumab treatment. Moreover, prior
laser-treated patients who could receive individualized
ranibizumab treatment at a later stage only (i.e., as of month
12) also achieved BCVA gain from month 12 to months 24
and 36. However, at month 24, the BCVA gain from core
baseline observed in the prior laser group was around 75%
of that achieved in the prior ranibizumab groups. At month
36, the patients in the prior laser group demonstrated a
BCVA gain similar to that observed in the prior ranibizumab
groups, but a gradual BCVA gain was observed in the prior
laser group over a period of 3 years when compared with the
rapid initial gain observed in the prior ranibizumab-treated
patients. We hypothesize that prolonged edematous stress
due to deferred ranibizumab treatment and subsequent
damage to neurosensory layers may have led to the delayed
VA gain observed in the prior laser-treated patients. How-
ever, this study was not designed to test this hypothesis;
further investigations are required to evaluate the retinal
damage associated with deferred ranibizumab treatment and
consequently to determine the appropriate timing for the
initiation of ranibizumab treatment.
The proportion of patients gaining 10 letters or 15
letters was somewhat similar across the 3 treatment groups
at month 36. However, a greater proportion of patients in the
prior laser group lost 10 letters and 15 letters than those
in the prior ranibizumab and prior ranibizumab þ laser
groups, underscoring the value of early ranibizumab therapy
in reducing the risk of signiﬁcant BCVA loss.
In patients treated with ranibizumab in the core and
extension studies, mean CRST decrease at month 12 was
maintained from month 12 to month 36. However, in pa-
tients treated with laser alone in the core study, mean CRST
observed at month 12 further decreased through month 36
with the allowance of ranibizumab in the extension study.
This ﬁnding demonstrates the anatomic effectiveness of
ranibizumab even in patients with long-standing DME. It is
reassuring that ranibizumab treatment over 3 years in the
prior ranibizumab groups or over 2 years in the prior laser
group was not associated with a considerable progression in
the foveal avascular zone. Furthermore, a greater proportion
of patients showed an improvement rather than worsening of
ETDRS severity scores with ranibizumab treatment over the
3-year study period.
In addition to the improvements in BCVA and CRST
from baseline to month 36, there was an overall improve-
ment in patient-reported visual functioning, as measured by
the NEI VFQ-25 subscale scores (composite, general vision,near activities, and distance activities) in patients who
received continuous ranibizumab treatment from the core
study. A substantial portion of the initial gain in the NEI
VFQ-25 scores was maintained in the prior ranibizumab
groups even with a low mean number of injections during
the extension study. Patients in the prior laser-treated group
showed an improvement in the NEI VFQ-25 subscale scores
from month 12 to months 24 to 36 after receiving ranibi-
zumab treatment in the extension study; however, for pa-
tients in the prior laser group, a period of approximately 3
years was required to achieve visual functioning beneﬁts
similar to those in the prior ranibizumab groups. Because
DME affects the working-age population,1 any delay in VA
gains may signiﬁcantly affect their ability to perform day-to-
day activities. Therefore, it is important to initiate prompt
ranibizumab treatment to provide VA beneﬁts at the earliest
opportunity.
One of the most relevant and beneﬁcial ﬁndings of this
long-term analysis is certainly the change in re-treatment
need over time. The individualized dosing regimen based on
VA stability and disease progression criteria was able to
maintain VA and provide optimal visual function beneﬁts in
prior ranibizumab-treated patients with decreasing fre-
quency of injections over time. The mean number of in-
jections received by the ranibizumab-treated patients from
day 1 to month 5 was 4.9 (median, 5.0) injections, including
the 3 mandatory loading injections. Patients treated with
ranibizumab from the core phase received an average of
13.9 injections (median, 12.0 injections) from day 1 to
month 35, with an average of 3.7 injections during the ﬁrst
year of the extension study, which further decreased to 2.7
injections in the ﬁnal year of the extension. Approximately
19% to 25% of patients across the treatment arms did not
require any ranibizumab injections during the extension
study. Therefore, patients treated with ranibizumab during
the entire study were, on average, able to maintain the
BCVA gained up to month 12 with fewer than 3 injections
during the ﬁnal year of the extension with the protocol-
speciﬁed re-treatment criteria. Almost every patient
(93.2%e100%) interrupted treatment at least once from
months 12 to 35 because of disease improvement.
The RESTORE extension results mirror those of the
DRCR.net study9 in which, over a period of 3 years, VA
was maintained with a diminishing number of injections.
However, in the DRCR.net study there were only
ranibizumab þ prompt laser or ranibizumab þ deferred
laser arms, excluding the possibility of evaluating whether
ranibizumab monotherapy could be as effective when
compared with ranibizumab combined with prompt or
deferred laser. Also, in contrast to the DRCR.net study,
the current study assessed the effects of ranibizumab
monotherapy over 3 years, although concomitant laser
treatment was allowed in the extension study. The re-
treatment criteria used in the current study are consistent
with the ranibizumab EU label and are simple to apply in
the context of clinical practice.9
The long-term RESTORE extension study provides
valuable information regarding the individualized dosing
regimen of ranibizumab during extended treatment in DME.
The progressive reduction in re-treatment needs is the most1051
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optimize the management of DME. However, it was beyond
the scope of this study to determine whether an alternate
treatment strategy such as “treat and extend” or PRN
treatment with less frequent than monthly monitoring could
result in a similar visual outcome compared with PRN
dosing, while potentially reducing the need for monthly
monitoring. Such an outcome is likely, given the ability to
extend follow-up intervals as found in the DRCR.net pro-
tocol.9 Unlike the individualized dosing regimen used in the
current study, a treat and extend regimen provides treatment
at any follow-up visit but increases the interval to the next
visit if vision is stable. The RETAIN study (registered as
NCT01171976 at http://clinicaltrials.gov/; accessed June 25,
2013) is expected to provide valuable information regarding
the efﬁcacy and safety of ranibizumab using an alternate
treat and extend dosing regimen.
Establishing the long-term safety proﬁle of retinal
vascular disease treatments is extremely important because
the retinal microvasculature is closely interlinked with the
cerebral microvasculature and abnormalities of the retinal
microvasculature are important predictors of cardiovascular
risks and mortality.13,14 Thus, any insult to the retinal
microvasculature may have an impact on the brain and
cardiovascular system. In addition, patients with DME are
also prone to systemic complications associated with dia-
betes,2 which further mandates the long-term safety moni-
toring of any treatments administered to these patients.
The results of this 3-year long-term study demonstrated
that ranibizumab treatment was generally well tolerated,
with no new ocular or systemic safety ﬁndings, consistent
with the safety observations in the RESTORE core and
interim studies.11,12 In the current study, ocular SAEs were
reported in 2.4% to 4.1% of the patients across the treatment
arms over 3 years, and the majority of the reported SAEs
were not suspected to be related to the study drug/procedure.
During the 3-year study period, a total of 2779 ranibi-
zumab injections were administered, with no reports of
endophthalmitis, suggesting that there was adequate adher-
ence to the aseptic injection procedure. Throughout the
study period, the most frequently reported ocular AEs were
cataract (16.3%) and eye pain (15.4%), and the most
frequently reported nonocular AEs were nasopharyngitis
(23.3%) and hypertension (13.3%), which were reported in
similar frequencies across the 3 prior treatment groups.
Among the 240 patients entering the extension study, 8
deaths were reported, none of which were suspected to be
related to the study drug/treatment procedure. The safety
proﬁle of ranibizumab in this 3-year study is consistent with
the safety proﬁle of ranibizumab observed in other DME
trials and in trials involving patients with age-related mac-
ular degeneration and retinal vein occlusion.6e9,11,12,15e19
In terms of study limitations, patients with stroke and
transient ischemic attack were excluded from this study in
contrast to the real-life setting where there is a possibility
that a more diverse patient population with multiple co-
morbid conditions would receive ranibizumab therapy.
Thus, the safety results of this study should be interpreted
relative to this exclusion. In addition, this extension study
enrolled 240 patients and was not powered to assess the1052occurrence rate of infrequent but important SAEs, including
systemic events (e.g., stroke). Long-term studies such as
LUMINOUS (registered as NCT01318941 at http://clin-
icaltrials.gov/; accessed June 25, 2013) conducted in a broad
patient population will help to further describe the long-term
safety proﬁle, effectiveness, and treatment patterns of rani-
bizumab in a real-life setting.
In conclusion, the 3-year results of the RESTORE
extension study conﬁrmed the favorable efﬁcacy and safety
proﬁles of ranibizumab in the long-term treatment of visual
impairment due to DME. Ranibizumab treatment was
generally well tolerated, and there were no new ocular or
systemic AEs. The safety proﬁle of ranibizumab observed in
this study is consistent with the well-established safety
proﬁle of ranibizumab. This study also demonstrated that
individualized treatment was able to consistently maintain
VA in the ranibizumab-treated patients. Of note, the number
of injections required during the extended follow-up
declined progressively, enabling optimized strategies for
long-term management of DME with intravitreal ranibizu-
mab. Across the 3 treatment arms, 19% to 25% of patients
did not require any ranibizumab injections during the
extension study. Therapeutic beneﬁt of ranibizumab was
also observed in the prior laser-treated patients, who could
receive ranibizumab only during the extension study.
Although patients in the prior laser group were ﬁnally able
to achieve approximately 75% of the beneﬁt seen in the
ranibizumab monotherapy group, after receiving ranibizu-
mab in the extension study, this gain was gradual and
occurred over the 2-year period of the extension. Thus, early
initiation of ranibizumab therapy may provide prompt and
substantial VA gains allowing patients from the working-
age population, often challenged by multiple systemic
comorbidities, to ease disease management and improve
quality of life despite severe and chronic disease.
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